The CANVAS Program: Implications of Canagliflozin on Reducing Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus

Cardiovascular Diabetology - United Kingdom
doi 10.1186/s12933-019-0869-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes

Clinical Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Effect of Canagliflozin on Serum Uric Acid in Patients With Type 2 Diabetes Mellitus

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Canagliflozin Improves Risk Factors of Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus and Metabolic Syndrome

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2017English

Cardiovascular Risk in Patients With Type 2 Diabetes

CMAJ
Medicine
2005English

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Advances in Therapy
MedicinePharmacology
2015English

Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk

Journal of Managed Care Pharmacy
2007English

Risk Factors in Patients With Type 2 Diabetes Mellitus

Revista Latino-Americana de Enfermagem
Nursing
2008English

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results From the CANVAS Program

Circulation
Cardiovascular MedicinePhysiologyCardiology
2019English

Evidence of Suboptimal Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Symptomatic Atherosclerosis

CMAJ
Medicine
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy